


WE CLAIM:

1. A method for the treatment of a mammal infected with a virus of the *Flaviviridae* family comprising administering a therapeutically effective amount of a compound of Formula (I):



Formula (I)

wherein **A** is selected from: C₁ to C₆ alkyl and C₃ to C₆ cycloalkyl; **B** is selected from: phenyl or thiazolyl, both of which optionally substituted with a group selected from NH(R¹) and NH(CO)R¹, wherein R¹ is C₁ to C₆ alkyl; and **R** is OH or a sulfonamide group of the formula -NHSO₂-R² wherein R² is -(C₁₋₈)alkyl, -(C₃₋₇)cycloalkyl or {-(C₁₋₆)alkyl-(C₃₋₆)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O-(C₁₋₆)alkyl, amido, amino or phenyl, or R² is C₆ or C₁₀ aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C₁₋₆)alkyl, O-(C₁₋₆)alkyl, amido, amino or phenyl; or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein **A** of Formula (I) is a branched C₄ to C₆ alkyl or C₄ to C₆ cycloalkyl group, **B** of Formula (I) is phenyl or a thiazole substituted at position 2 with NH(R¹) or NH(CO)R¹ in which R¹ is a C₁ to C₄ alkyl, and **R** is OH or a sulfonamide group of formula -NHSO₂-R² wherein R² is -(C₁₋₆)alkyl, -(C₃₋₆)cycloalkyl, both optionally substituted 1 or 2 times with halo or phenyl, or R² is C₆ aryl optionally substituted from 1 or 2 times with halo or (C₁₋₆)alkyl.
3. The method according to claim 2, wherein **A** is cyclopentyl or *tert*-butyl, **B** is a thiazole substituted at position 2 with NH(R¹) or NH(CO)R¹ in which R¹ is a C₁ to C₄ alkyl, and **R** is OH or a sulfonamide group wherein R² is methyl, cyclopropyl or phenyl.

4. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is Yellow Fever virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with $\text{NHCH}(\text{CH}_3)_2$, and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.
5. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is West Nile virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with $\text{NHCH}(\text{CH}_3)_2$, and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.
6. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is Dengue fever virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with $\text{NHCH}(\text{CH}_3)_2$, and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.
7. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is Japanese Encephalitis virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with $\text{NHCH}(\text{CH}_3)_2$, and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.
8. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is GB virus A or C, and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with $\text{NHCH}(\text{CH}_3)_2$, and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.
9. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is Hepatitis G virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with

NHCH(CH₃)₂, and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.

10. The method according to claim 1, wherein said mammal is a cattle, said Flaviviridae is BVDV and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with NHCH(CH₃)₂, and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.
11. The method according to claim 1, wherein said mammal is a sheep, said Flaviviridae is border disease virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with NHCH(CH₃)₂, and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.
12. The method according to claim 1, wherein said mammal is a pig, said Flaviviridae is Classical Swine Fever Virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with NHCH(CH₃)₂, and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.
13. The method according to claim 1, wherein said Flaviviridae virus comprises an NS3 protease comprising amino acid residues selected from: H57, G137, S139, A156 and A157.
14. An article of manufacture comprising packaging material contained within which is a composition effective to inhibit a virus of the *Flaviviridae* family and the packaging material comprises a label which indicates that the composition can be used to treat infection by a virus of the *Flaviviridae* family and, wherein said composition comprises a compound of Formula (I) as defined in claim 1.